A Phase 1/2 open label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG 701 monotherapy, or in combination with Pomalidomide, with and without Dexamethasone in subjects with relapsed or refractory Multiple Myeloma (ParadigMM-1B)

Protocol No
AMGEN-20170122-AMG701
Principal Investigator
Parameswaran Hari
Phase
I
Summary
This study will see if AMG 701 is safe and tolerable and whether it causes any side effects. This study will also look at what doses of AMG 701 are safe for people to take and what the effect on Multiple Myeloma is.
Description
A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: